Ex-Senator Ben Sasse Enters Groundbreaking Pancreatic Cancer Trial
TL;DR
Former U.S. senator Ben Sasse, diagnosed with metastatic pancreatic cancer, joined Revolution Medicines’ frontline trial of daraxonrasib. Preliminary topline data show the drug can markedly extend survival versus chemotherapy in second-line use, and Sasse reports dramatic drops in the tumor marker CA 19-9 and meaningful pain relief, with frontline use potentially even more beneficial, signaling a potential major advance in pancreatic cancer care.
Topics:businesshealth#clinical-trial#daraxonrasib#health#md-anderson#pancreatic-cancer#revolution-medicines
- For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option statnews.com
- Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial CNBC
- Daraxonrasib Yields Significant Survival Advantages vs Chemotherapy in Metastatic Pancreatic Cancer OncLive
- First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know Pancreatic Cancer Action Network
- Revolution Medicines Stock Is Soaring 39%. Here’s Why. Barron's
Want the full story? Read the original reporting
Read on statnews.com